On the 19th, the Blockchain Promotion Association (BCCC) announced that starting from July 2026, it will add JPYC, a Japanese yen-denominated electronic payment stablecoin, as a method for paying annual membership fees. The wallets that will support this are unWallet and HashPort Wallet, initially to be used for membership companies' annual fee payments.
The association describes this initiative as "the first attempt by an industry organization" (according to BCCC). Yoichiro Hirano, the representative director of BCCC and president of Asteria, stated, "This is the first step for the association to take a practical approach as a user," indicating a plan to accumulate and share tax and accounting knowledge with its members. The association is also considering expanding the usage scope to include operational expense payments and accommodating other stablecoins.
Noritaka Okabe, the representative director of JPYC Co., Ltd. and vice representative director of the association, also welcomed the announcement. He evaluated it as "an ideal solution for the operation of industry organizations, as it enables highly transparent accounting processes," expressing hope for its expanded use in other fields.
In Japan, the legal positioning of stablecoins was established with the revised Payment Services Act that came into effect in June 2023. JPYC began issuance in October 2025, and as of May 30, 2026, the issuance amount has surpassed 3 billion yen (according to JPYC Co., Ltd.).
BCCC has a track record of conducting a demonstration experiment with the yen-pegged stablecoin "Zen" in July 2017. The total issuance amount was approximately 850 million yen, with about 10 participating companies (according to BCCC). In February 2020, it established a subcommittee to continue technological enlightenment.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.














Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.